- Home
- REE vs ELDN Comparison
REE vs ELDN Comparison
Compare REE & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- ELDN
- Stock Information
- Founded
- REE 2011
- ELDN 2004
- Country
- REE Israel
- ELDN United States
- Employees
- REE N/A
- ELDN N/A
- Industry
- REE Auto Manufacturing
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- REE Consumer Discretionary
- ELDN Health Care
- Exchange
- REE Nasdaq
- ELDN Nasdaq
- Market Cap
- REE 201.6M
- ELDN 239.6M
- IPO Year
- REE N/A
- ELDN N/A
- Fundamental
- Price
- REE $10.28
- ELDN $4.28
- Analyst Decision
- REE Buy
- ELDN Strong Buy
- Analyst Count
- REE 3
- ELDN 1
- Target Price
- REE $11.00
- ELDN $16.00
- AVG Volume (30 Days)
- REE 95.4K
- ELDN 414.7K
- Earning Date
- REE 12-17-2024
- ELDN 11-12-2024
- Dividend Yield
- REE N/A
- ELDN N/A
- EPS Growth
- REE N/A
- ELDN N/A
- EPS
- REE N/A
- ELDN N/A
- Revenue
- REE $626,000.00
- ELDN N/A
- Revenue This Year
- REE N/A
- ELDN N/A
- Revenue Next Year
- REE $50,620.25
- ELDN N/A
- P/E Ratio
- REE N/A
- ELDN N/A
- Revenue Growth
- REE N/A
- ELDN N/A
- 52 Week Low
- REE $2.91
- ELDN $1.43
- 52 Week High
- REE $11.72
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- REE 57.38
- ELDN 50.60
- Support Level
- REE $8.70
- ELDN $4.32
- Resistance Level
- REE $11.63
- ELDN $4.76
- Average True Range (ATR)
- REE 1.09
- ELDN 0.40
- MACD
- REE 0.14
- ELDN -0.05
- Stochastic Oscillator
- REE 49.62
- ELDN 26.06
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is developing REEcorner technology which packs critical vehicle components into a single compact module positioned between the chassis and the wheel as well as building commercial Electric Vehicles (EV) leveraging REEcorner technology. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.